TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Vitamin D Supplementation on Host Immunity to Mycobacterium Tuberculosis and Response to Treatment: Building Translational Research Capacity in Nutrition and Infectious Diseases in the Republic of Georgia
Brief Summary: Tuberculosis bacterium (TB) is a germ that can infect any part of the human body, especially the lungs. Vitamin D is a hormone present in humans that regulates blood electrolytes such as calcium and phosphate. There is new information that links vitamin D to the functioning of our immune system. The purpose of the study is to find out how vitamin D affects the immune system of patients with TB. We want to find out if correcting low vitamin D levels, in addition to getting standard therapy for TB, will help the immune system fight off TB infection more effectively.

The study will be done at the Georgia National Center for Tuberculosis and Lung Diseases (NCTBLD) in Tbilisi, Republic of Georgia. 220 patients with tuberculosis and 80 family members or household contacts of patients with tuberculosis will be participating in this study. TB patients, already receiving standard TB therapy, will be randomly assigned to either receive the Vitamin D pill or a placebo for a total of sixteen weeks. Neither the subject nor the investigator will know whether the subject has received the Vitamin D or the inactive placebo.The subject will orally consume the Vitamin D/placebo tablet 3 times a week for the 1st 8 weeks (while in hospital) and then once every other week for the last 8 weeks( during out-patient visits to the hospital).

The main study hypothesis is that Vitamin D supplementation helps patients with tuberculosis, who are on standard anti TB antibiotic therapy, get better faster.


Options:
A: Intervention Type: DRUG; Name: Cholecalciferol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Migliol Placebo Oil; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: food; Assigned to Arm(s): N/A
C: Arm Label: Vitamin D pill; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D pill | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D pill; Assigned to Arm(s): Vitamin D pill | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: L-arginine, Drug: Vitamin D | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D, Drug: Placebo L-arginine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: L-arginine, Drug: Placebo Vitamin D | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo L-arginine, Drug: Placebo Vitamin D | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo L-arginine; Assigned to Arm(s): 2, 4 | Intervention Type: DRUG; Name: Placebo Vitamin D; Assigned to Arm(s): 3, 4

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Use of Educational Videos to Improve Patient Decision Making and Racial Disparities in the Implantation of Implantable Cardioverter Defibrillators (ICDs)
Brief Summary: The investigators will examine whether an educational video increases patient knowledge about heart failure and the risk of sudden cardiac arrest and leads to greater satisfaction with information provided as compared to usual care. Additionally, the investigators will look at whether racial concordance (physician and patient being of the same race) improves satisfaction with the patient's treatment decision and disease knowledge. Our hypothesis is that a video in which participants are of the same race as the patient will provide better education and more satisfaction with the treatment decision and may lead to more patients choosing ICD therapy.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: evidence based decision aid, Behavioral: Possible reimbursement 4th IVF/ICSI cycle when necessary | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: evidence based decision aid; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Possible reimbursement 4th IVF/ICSI cycle when necessary; Assigned to Arm(s): 1
B: Arm Label: Usual Support Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual-Support | Arm Label: Enhanced Support Group; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Support | Intervention Type: BEHAVIORAL; Name: Enhanced Support; Assigned to Arm(s): Enhanced Support Group | Intervention Type: BEHAVIORAL; Name: Usual-Support; Assigned to Arm(s): Usual Support Group
C: Arm Label: P4; Type: EXPERIMENTAL; Interventions: Behavioral: P4 | Arm Label: Usual care+; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: P4; Assigned to Arm(s): P4
D: Arm Label: White educational video; Type: N/A; Interventions: N/A | Arm Label: African-American educational video; Type: N/A; Interventions: N/A | Arm Label: Usual care; Type: N/A; Interventions: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Use of Educational Videos to Improve Patient Decision Making and Racial Disparities in the Implantation of Implantable Cardioverter Defibrillators (ICDs)
Brief Summary: The investigators will examine whether an educational video increases patient knowledge about heart failure and the risk of sudden cardiac arrest and leads to greater satisfaction with information provided as compared to usual care. Additionally, the investigators will look at whether racial concordance (physician and patient being of the same race) improves satisfaction with the patient's treatment decision and disease knowledge. Our hypothesis is that a video in which participants are of the same race as the patient will provide better education and more satisfaction with the treatment decision and may lead to more patients choosing ICD therapy.


Options:
A: Arm Label: White educational video; Type: N/A; Interventions: N/A | Arm Label: African-American educational video; Type: N/A; Interventions: N/A | Arm Label: Usual care; Type: N/A; Interventions: N/A
B: Arm Label: Decision Aid; Type: OTHER; Interventions: Other: Decision Aid | Arm Label: Standard; Type: OTHER; Interventions: Other: Standard | Intervention Type: OTHER; Name: Decision Aid; Assigned to Arm(s): Decision Aid | Intervention Type: OTHER; Name: Standard; Assigned to Arm(s): Standard
C: Arm Label: Shared Decision Making/Brief Negotiated Interviewing; Type: OTHER; Interventions: Behavioral: Shared Decision Making | Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Shared Decision Making; Assigned to Arm(s): Shared Decision Making/Brief Negotiated Interviewing
D: Arm Label: Abbreviated Consenting; Type: EXPERIMENTAL; Interventions: Procedure: Abbreviated HIV test counseling | Arm Label: Standard Consenting; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Abbreviated HIV test counseling; Assigned to Arm(s): Abbreviated Consenting

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa
Brief Summary: This study will investigate how well adalimumab works in people with hidradenitis suppurativa (HS) in the short and long term.


Options:
A: Arm Label: infliximab; Type: EXPERIMENTAL; Interventions: Drug: infliximab, Drug: Placebo Comparator | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator | Intervention Type: DRUG; Name: infliximab; Assigned to Arm(s): infliximab | Intervention Type: DRUG; Name: Placebo Comparator; Assigned to Arm(s): Placebo, infliximab
B: Intervention Type: PROCEDURE; Name: Long-pulsed Nd:YAG laser 1064 nm; Assigned to Arm(s): N/A
C: Arm Label: Adalimumab 40 mg qwk; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Adalimumab 40 mg eow; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 40 mg eow, Adalimumab 40 mg qwk | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: placebo controlled; Type: N/A; Interventions: Drug: etanercept | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): placebo controlled

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of the Efficacy and Safety of Varenicline Versus Placebo for Smoking Cessation Among HIV-infected Patients. A Randomized Double Blind Controlled Trial
Brief Summary: Cigarette smoking is a major cause of illness among HIV-infected patients (non-AIDS defining malignancies (especially lung cancer), non-AIDS bacterial infections and cardio-vascular diseases). Approximately 50% of HIV-infected patients are regular tobacco smokers. Tobacco smoking cessation has well known benefits on mortality and morbidity in the general population where tobacco cessation assistance programs are increasingly implemented. However, smoking cessation interventions have never been evaluated among HIV-infected patients. This trial aims at evaluating the efficacy and safety of varenicline for smoking cessation compared with placebo.


Options:
A: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Varenicline + Active Patch; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch, Drug: Varenicline | Arm Label: Varenicline + Placebo Patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Varenicline | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Varenicline + Active Patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Varenicline + Placebo Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Patch, Varenicline + Placebo Patch
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline tartrate | Arm Label: bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion hydrochloride | Arm Label: Nicotine Replacement Therapy Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Replacement Therapy Patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline tartrate; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: bupropion hydrochloride; Assigned to Arm(s): bupropion | Intervention Type: DRUG; Name: Nicotine Replacement Therapy Patch; Assigned to Arm(s): Nicotine Replacement Therapy Patch
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartarate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline Tartarate; Assigned to Arm(s): varenicline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of the Efficacy and Safety of Varenicline Versus Placebo for Smoking Cessation Among HIV-infected Patients. A Randomized Double Blind Controlled Trial
Brief Summary: Cigarette smoking is a major cause of illness among HIV-infected patients (non-AIDS defining malignancies (especially lung cancer), non-AIDS bacterial infections and cardio-vascular diseases). Approximately 50% of HIV-infected patients are regular tobacco smokers. Tobacco smoking cessation has well known benefits on mortality and morbidity in the general population where tobacco cessation assistance programs are increasingly implemented. However, smoking cessation interventions have never been evaluated among HIV-infected patients. This trial aims at evaluating the efficacy and safety of varenicline for smoking cessation compared with placebo.


Options:
A: Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): N/A
B: Arm Label: High-intensity group; Type: EXPERIMENTAL; Interventions: Other: High-intensity smoking cessation intervention | Arm Label: Low-intensity group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low-intensity smoking cessation intervention | Intervention Type: OTHER; Name: High-intensity smoking cessation intervention; Assigned to Arm(s): High-intensity group | Intervention Type: DRUG; Name: Low-intensity smoking cessation intervention; Assigned to Arm(s): Low-intensity group
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline tartrate | Arm Label: bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion hydrochloride | Arm Label: Nicotine Replacement Therapy Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Replacement Therapy Patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline tartrate; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: bupropion hydrochloride; Assigned to Arm(s): bupropion | Intervention Type: DRUG; Name: Nicotine Replacement Therapy Patch; Assigned to Arm(s): Nicotine Replacement Therapy Patch

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Sangustop® as Haemostatic Agent Versus a Carrier-bound Fibrin Sealant During Liver Resection (ESSCALIVER)
Brief Summary: This is a multi-centre, patient-blinded, intra-operatively randomised controlled trial. A total of 126 patients planned for an elective liver resection will be enrolled in 9 surgical centres. The primary objective of this study is to show that the collagen based haemostatic device Sangustop® is not inferior to a carrier-bound fibrin sealant (Tachosil®) in achieving haemostasis after hepatic resection.


Options:
A: Arm Label: Fibrin Pad; Type: EXPERIMENTAL; Interventions: Biological: Fibrin Pad | Arm Label: Standard of Care; Type: OTHER; Interventions: Procedure: Standard of Care | Intervention Type: BIOLOGICAL; Name: Fibrin Pad; Assigned to Arm(s): Fibrin Pad | Intervention Type: PROCEDURE; Name: Standard of Care; Assigned to Arm(s): Standard of Care
B: Arm Label: Sangustop; Type: EXPERIMENTAL; Interventions: Device: Sangustop | Arm Label: Tachosil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tachosil | Intervention Type: DEVICE; Name: Sangustop; Assigned to Arm(s): Sangustop | Intervention Type: DRUG; Name: Tachosil; Assigned to Arm(s): Tachosil
C: Arm Label: Fibrocaps + Gelatin Sponge; Type: EXPERIMENTAL; Interventions: Biological: Fibrocaps, Biological: Gelatin sponge | Arm Label: Gelatin Sponge; Type: ACTIVE_COMPARATOR; Interventions: Biological: Gelatin sponge | Intervention Type: BIOLOGICAL; Name: Fibrocaps; Assigned to Arm(s): Fibrocaps + Gelatin Sponge | Intervention Type: BIOLOGICAL; Name: Gelatin sponge; Assigned to Arm(s): Fibrocaps + Gelatin Sponge, Gelatin Sponge
D: Arm Label: Standard Care; Type: PLACEBO_COMPARATOR; Interventions: Drug: No tranexamic acid | Arm Label: Dose 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Arm Label: Dose 2; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Intervention Type: DRUG; Name: No tranexamic acid; Assigned to Arm(s): Standard Care | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Dose 1, Dose 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Sangustop® as Haemostatic Agent Versus a Carrier-bound Fibrin Sealant During Liver Resection (ESSCALIVER)
Brief Summary: This is a multi-centre, patient-blinded, intra-operatively randomised controlled trial. A total of 126 patients planned for an elective liver resection will be enrolled in 9 surgical centres. The primary objective of this study is to show that the collagen based haemostatic device Sangustop® is not inferior to a carrier-bound fibrin sealant (Tachosil®) in achieving haemostasis after hepatic resection.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Normovolemic Hemodilution (ANH) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard of care | Intervention Type: PROCEDURE; Name: Normovolemic Hemodilution (ANH); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Standard of care; Assigned to Arm(s): 2
B: Arm Label: Fibrocaps + Gelatin Sponge; Type: EXPERIMENTAL; Interventions: Biological: Fibrocaps, Biological: Gelatin sponge | Arm Label: Gelatin Sponge; Type: ACTIVE_COMPARATOR; Interventions: Biological: Gelatin sponge | Intervention Type: BIOLOGICAL; Name: Fibrocaps; Assigned to Arm(s): Fibrocaps + Gelatin Sponge | Intervention Type: BIOLOGICAL; Name: Gelatin sponge; Assigned to Arm(s): Fibrocaps + Gelatin Sponge, Gelatin Sponge
C: Arm Label: Clamp-Crush technique; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Clamp-Crush technique | Arm Label: Stapler hepatectomy; Type: EXPERIMENTAL; Interventions: Procedure: Stapler hepatectomy | Intervention Type: PROCEDURE; Name: Clamp-Crush technique; Assigned to Arm(s): Clamp-Crush technique | Intervention Type: PROCEDURE; Name: Stapler hepatectomy; Assigned to Arm(s): Stapler hepatectomy
D: Arm Label: Sangustop; Type: EXPERIMENTAL; Interventions: Device: Sangustop | Arm Label: Tachosil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tachosil | Intervention Type: DEVICE; Name: Sangustop; Assigned to Arm(s): Sangustop | Intervention Type: DRUG; Name: Tachosil; Assigned to Arm(s): Tachosil

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study in Cystic Fibrosis (CF) Subjects to Assess Efficacy, Safety and Pharmacokinetics of Tobramycin Inhalation Powder From a Modified Manufacturing Process (TIPnew).
Brief Summary: This study is designed to show how well tobramycin inhalation powder works and how safe it is when produced by a modified manufacturing process


Options:
A: Arm Label: Aeroquin; Type: EXPERIMENTAL; Interventions: Drug: MP-376 (Levofloxacin Solution for Inhalation) | Arm Label: TIS; Type: ACTIVE_COMPARATOR; Interventions: Drug: TIS (Tobramycin Inhalation Solution) | Intervention Type: DRUG; Name: MP-376 (Levofloxacin Solution for Inhalation); Assigned to Arm(s): Aeroquin | Intervention Type: DRUG; Name: TIS (Tobramycin Inhalation Solution); Assigned to Arm(s): TIS
B: Arm Label: CF patients with pulmonary exacerbations; Type: N/A; Interventions: N/A
C: Arm Label: azithromycin and TIS; Type: ACTIVE_COMPARATOR; Interventions: Drug: azithromycin, Drug: Tobramycin solution for inhalation | Arm Label: placebo and TIS; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Drug: Tobramycin solution for inhalation | Intervention Type: DRUG; Name: azithromycin; Assigned to Arm(s): azithromycin and TIS | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo and TIS | Intervention Type: DRUG; Name: Tobramycin solution for inhalation; Assigned to Arm(s): azithromycin and TIS, placebo and TIS
D: Arm Label: TIP (Tobramycin Inhalation Powder); Type: EXPERIMENTAL; Interventions: Drug: Tobramycin Inhalation Powder | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tobramycin Inhalation Powder; Assigned to Arm(s): TIP (Tobramycin Inhalation Powder) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study in Cystic Fibrosis (CF) Subjects to Assess Efficacy, Safety and Pharmacokinetics of Tobramycin Inhalation Powder From a Modified Manufacturing Process (TIPnew).
Brief Summary: This study is designed to show how well tobramycin inhalation powder works and how safe it is when produced by a modified manufacturing process


Options:
A: Arm Label: CF patients with pulmonary exacerbations; Type: N/A; Interventions: N/A
B: Arm Label: Cohort 1 - 280 mg ARIKACE™; Type: EXPERIMENTAL; Interventions: Drug: ARIKACE™ | Arm Label: Cohort 1 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort 2 - 560 mg ARIKACE™; Type: EXPERIMENTAL; Interventions: Drug: ARIKACE™ | Arm Label: Cohort 2 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ARIKACE™; Assigned to Arm(s): Cohort 1 - 280 mg ARIKACE™, Cohort 2 - 560 mg ARIKACE™ | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 - Placebo, Cohort 2 - Placebo
C: Arm Label: Observational; Type: N/A; Interventions: N/A
D: Arm Label: TIP (Tobramycin Inhalation Powder); Type: EXPERIMENTAL; Interventions: Drug: Tobramycin Inhalation Powder | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tobramycin Inhalation Powder; Assigned to Arm(s): TIP (Tobramycin Inhalation Powder) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Buzzy: An Integration of Vibration, Cold, and Distraction for Pediatric Needle Pain Relief
Brief Summary: A vibrating cold pack placed proximal to the site of venipuncture will decrease the pain of cannulation when compared to vapocoolant spray.


Options:
A: Arm Label: Standard Care; Type: OTHER; Interventions: Other: vapocoolant | Arm Label: Buzzy; Type: EXPERIMENTAL; Interventions: Device: Buzzy | Intervention Type: DEVICE; Name: Buzzy; Assigned to Arm(s): Buzzy | Intervention Type: OTHER; Name: vapocoolant; Assigned to Arm(s): Standard Care
B: Arm Label: Standard intervention; Type: SHAM_COMPARATOR; Interventions: Other: standard | Arm Label: clown care; Type: EXPERIMENTAL; Interventions: Behavioral: clown care | Intervention Type: OTHER; Name: standard; Assigned to Arm(s): Standard intervention | Intervention Type: BEHAVIORAL; Name: clown care; Assigned to Arm(s): clown care
C: Arm Label: Conventional syringe; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Camouflage syringe; Type: EXPERIMENTAL; Interventions: Procedure: Camouflage syringe | Intervention Type: PROCEDURE; Name: Camouflage syringe; Assigned to Arm(s): Camouflage syringe
D: Arm Label: Standard technique; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard technique | Arm Label: Parent participation technique; Type: EXPERIMENTAL; Interventions: Behavioral: Parent participation technique | Intervention Type: BEHAVIORAL; Name: Standard technique; Assigned to Arm(s): Standard technique | Intervention Type: BEHAVIORAL; Name: Parent participation technique; Assigned to Arm(s): Parent participation technique

Answer: A